About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Bscl2
BSCL2 lipid droplet biogenesis associated, seipin
MGI:1298392
121 phenotypes from 6 alleles in 7 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Bscl2tm1.1Gliu/Bscl2tm1.1Gliu
Tg(Ddx4-cre)1Dcas/0
involves: 129 * 129S4/SvJaeSor * FVB/N 		abnormal male germ cell morphology J:211072
abnormal phospholipid level J:211072
abnormal sperm flagellum morphology J:211072
abnormal sperm head morphology J:211072
abnormal spermatid morphology J:211072
abnormal spermatogenesis J:211072
abnormal spermiogenesis J:211072
abnormal testis morphology J:211072
normal adipose tissue phenotype J:211072
asthenozoospermia J:211072
normal homeostasis/metabolism phenotype J:211072
male infertility J:211072
oligozoospermia J:211072
teratozoospermia J:211072
Bscl2tm1.1Gliu/Bscl2tm1.1Gliu
Tg(Fabp4-cre)1Rev/0
involves: 129 * 129S4/SvJaeSor 		increased circulating cholesterol level J:211072
increased circulating insulin level J:211072
lipodystrophy J:211072
normal reproductive system phenotype J:211072
Bscl2tm1.1Lchan/Bscl2tm1.1Lchan
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J 		abnormal aerobic respiration J:183701
abnormal cellular respiration J:183701
abnormal epididymal fat pad morphology J:211142
abnormal fat cell differentiation J:183701
abnormal fat pad morphology J:183701
abnormal glucose homeostasis J:183701
abnormal lipid homeostasis J:183701
abnormal lipid metabolism J:211142
abnormal small intestine morphology J:183701
abnormal white adipose tissue amount J:183701
abnormal white adipose tissue morphology J:211142
abnormal white adipose tissue physiology J:211142
abnormal white fat cell morphology J:183701
decreased body size J:183701
decreased body weight J:183701
decreased brown adipose tissue amount J:183701
decreased circulating adiponectin level J:183701
decreased circulating free fatty acids level J:183701
decreased circulating glucose level J:183701
decreased circulating glycerol level J:183701
decreased circulating leptin level J:183701
decreased circulating triglyceride level J:183701
decreased gonadal fat pad weight J:183701
decreased interscapular fat pad weight J:183701
decreased renal fat pad weight J:183701
decreased subcutaneous adipose tissue amount J:183701
decreased total body fat amount J:183701
decreased white adipose tissue amount J:211142
decreased white fat cell number J:183701
decreased white fat cell size J:183701
enhanced lipolysis J:183701
enlarged heart J:183701
enlarged kidney J:183701
enlarged liver J:183701
enlarged spleen J:183701
hepatic steatosis J:183701
increased circulating free fatty acids level J:183701
increased circulating glucose level J:183701
increased circulating glycerol level J:183701
increased circulating insulin level J:183701
increased circulating triglyceride level J:183701
increased lean body mass J:183701
insulin resistance J:183701
polyphagia J:183701
postnatal lethality, incomplete penetrance J:183701
Bscl2tm1.2Gliu/Bscl2tm1.2Gliu
involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB/N 		abnormal epididymal fat pad morphology J:173404
abnormal hypodermis fat layer morphology J:173404
abnormal male germ cell morphology J:211072
abnormal phospholipid level J:211072
abnormal sperm flagellum morphology J:211072
abnormal sperm head morphology J:211072
abnormal spermatid morphology J:211072
abnormal spermatogenesis J:211072
abnormal spermiogenesis J:211072
abnormal testis morphology J:211072
abnormal white fat cell differentation J:173404
asthenozoospermia J:211072
decreased body size J:173404
decreased brown adipose tissue amount J:173404
decreased circulating adiponectin level J:173404
decreased circulating leptin level J:173404
decreased gonadal fat pad weight J:173404
decreased inguinal fat pad weight J:173404
decreased mesenteric fat pad weight J:173404
decreased retroperitoneal fat pad weight J:173404
decreased subcutaneous adipose tissue amount J:173404
decreased total body fat amount J:173404
enlarged liver J:173404
enlarged spleen J:173404
impaired glucose tolerance J:173404
increased body temperature J:173404
increased circulating cholesterol level J:173404, J:211072
increased circulating glucose level J:173404
increased circulating insulin level J:173404, J:211072
increased circulating triglyceride level J:173404
increased liver triglyceride level J:173404
insulin resistance J:173404
lipodystrophy J:211072
normal liver/biliary system phenotype J:173404
macrovesicular hepatic steatosis J:173404
male infertility J:211072
microvesicular hepatic steatosis J:173404
oligozoospermia J:211072
teratozoospermia J:211072
Bscl2tm1b(EUCOMM)Hmgu/Bscl2tm1b(EUCOMM)Hmgu
C57BL/6N-Bscl2tm1b(EUCOMM)Hmgu/Ics 		abnormal bone structure J:211773
abnormal gait J:211773
decreased body length J:211773
decreased bone mineral content J:211773
decreased erythrocyte cell number J:211773
decreased locomotor activity J:211773
decreased prepulse inhibition J:211773
decreased respiratory quotient J:211773
decreased total body fat amount J:211773
decreased total retina thickness J:211773
improved glucose tolerance J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating calcium level J:211773
increased circulating cholesterol level J:211773
increased circulating glucose level J:211773
increased circulating HDL cholesterol level J:211773
increased circulating phosphate level J:211773
increased circulating serum albumin level J:211773
increased circulating total protein level J:211773
increased cornea thickness J:211773
increased fasting circulating glucose level J:211773
increased fluid intake J:211773
increased food intake J:211773
increased large unstained cell number J:211773
increased lean body mass J:211773
increased mean corpuscular hemoglobin J:211773
increased mean corpuscular volume J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
short tibia J:211773
Bscl2tm1c(EUCOMM)Hmgu/Bscl2tm1c(EUCOMM)Hmgu
Tg(Adipoq-cre)1Evdr/0
involves: C57BL/6N * FVB/NJ 		abnormal brown adipose tissue morphology J:260853
abnormal infrapatellar fat pad morphology J:260853
abnormal triglyceride level J:260853
abnormal white adipose tissue morphology J:260853
browned white adipose tissue morphology J:260853
decreased body fat mass J:260853
decreased bone marrow adipose tissue amount J:260853
decreased brown adipose tissue mass J:260853
decreased circulating adiponectin level J:260853
decreased locomotor activity J:260853
decreased respiratory quotient J:260853
decreased subcutaneous adipose tissue amount J:260853
decreased susceptibility to diet-induced obesity J:260853
decreased white adipose tissue amount J:260853
normal homeostasis/metabolism phenotype J:260853
increased lean body mass J:260853
increased liver triglyceride level J:260853
increased respiratory quotient J:260853
lipodystrophy J:260853
Bscl2tm1Geno/Bscl2tm1Geno
B6.129P2-Bscl2tm1Geno 		abnormal adipose tissue development J:200947
abnormal epididymis morphology J:200947
abnormal intestine morphology J:200947
abnormal lipid homeostasis J:200947
normal behavior/neurological phenotype J:200947
decreased body weight J:200947
decreased carbon dioxide production J:200947
decreased circulating adiponectin level J:200947
decreased circulating free fatty acids level J:200947
decreased circulating leptin level J:200947
decreased circulating triglyceride level J:200947
decreased energy expenditure J:200947
decreased gonadal fat pad weight J:200947
decreased inguinal fat pad weight J:200947
decreased interscapular fat pad weight J:200947
decreased mesenteric fat pad weight J:200947
decreased oxygen consumption J:200947
enhanced lipolysis J:200947
enlarged liver J:200947
hepatic steatosis J:200947
normal homeostasis/metabolism phenotype J:200947
hyperglycemia J:200947
impaired glucose tolerance J:200947
increased brown adipose tissue amount J:200947
increased circulating glucose level J:200947
increased circulating HDL cholesterol level J:200947
increased circulating insulin level J:200947
increased food intake J:200947
increased liver triglyceride level J:200947
increased liver weight J:200947
insulin resistance J:200947
lipodystrophy J:200947
male infertility J:200947
preweaning lethality, incomplete penetrance J:200947
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory